Robert S. Alter, MD

Drs Alter and Diamond muse about the unmet needs in advanced RCC treatment.

A discussion on the role of the cabozantinib and nivolumab regimen in the treatment of advanced RCC.

Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.

Elan Diamond, MD, describes when and how often community oncologists refer patients with suspected advanced renal cell carcinoma to his practice.

Oncologists review the IO/IO combination regimens available for treatment of advanced RCC and discuss patient selection for treatment with nivolumab and ipilimumab.

Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.

Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.

Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.

A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.